Effects of FR-91 on Immune Cells from Healthy Individuals and from Patients with Non-Hodgkin Lymphoma

Table 1

Effect of FR-91 on peripheral blood mononuclear cell (PBMC) subsets from healthy subjects.

	CD3/control	CD3/FR-91 10 𝜇g/mL	CD3/FR-91 25 𝜇g/mL
X*	65.59	73.48	75.26
SD^**	10.92	5.87	8.43
CV^***	0.16	0.08	0.11
P^****		.024	.022
	HLA-DR/control	HLA-DR/FR-91 10 𝜇g/mL	HLA-DR/FR-91 25 𝜇g/mL
X	4.48	3.26	3.65
SD	3.54	1.49	1.66
CV	0.79	0.45	0.45
P		.27	.84
	CD4/control	CD4/FR-91 10 𝜇g/mL	CD4/FR-91 25 𝜇g/mL
X	43.81	47.24	46.21
SD	11.8	7.9	9.6
CV	0.27	0.17	0.2
P		.15	.35
	CD25/control	CD25/FR-91 10 𝜇g/mL	CD25/FR-91 25 𝜇g/mL
X	5.5	5.47	6
SD	3.7	3.47	3.83
CV	0.67	0.63	0.64
P		.9	.42
	CD8/control	CD8/FR-91 10 𝜇g/mL	CD8/FR-91 25 𝜇g/mL
X	29.46	25.04	25.72
SD	8.91	4.41	5.37
CV	0.3	0.17	0.21
P		.029	.05
	CD69/control	CD69/FR-91 10 𝜇g/mL	CD69/FR-91 25 𝜇g/mL
X	13.76	10.04	11.1
SD	10.87	4.57	5.67
CV	0.79	0.46	0.51
P		.14	.26

𝑛=15;   *mean; ^**standard deviation; ^***coefficient of variation; ^****<.05: significant values.